Kuros Biosciences AG

EQS-Adhoc: Kuros Biosciences Invites to the Annual Shareholders' Meeting 2016

EQS Group-Ad-hoc: Kuros Biosciences AG / Key word(s): AGM/EGM
Kuros Biosciences Invites to the Annual Shareholders' Meeting 2016

26.05.2016 / 07:00
Release of an ad hoc announcement pursuant to Art. 53 KR.
The issuer is solely responsible for the content of this announcement.

Kuros Invites to the Annual Shareholders' Meeting 2016

Schlieren (Zurich), Switzerland, May 26, 2016 - Kuros Biosciences Ltd ("Kuros")
today announced that the Annual Shareholders' Meeting 2016 will take place on
Thursday, June 16, 2016 at 1 p.m. at the Company's offices in Schlieren/Zurich
(Switzerland). The Board of Directors proposes to carry out a reverse stock
split at the ratio of 100 to 1 and to amend the Articles of Association

The capital restructuring measures in 2015 and 2016 resulted in a nominal value
of CHF 0.01 per registered share. To simplify the trading and to increase the
shares' attractiveness for investors, the Board proposes to carry out a reverse
stock split at the ratio of 100 to 1 with the effect that 100 registered shares
with a nominal value of CHF 0.01 each will be exchanged into 1 new (merged)
registered share with a nominal value of CHF 1.00. The current shareholders and
founders Dr. Jeffrey Hubbell and Didier Cowling have committed for no
consideration to providing the other shareholders with the number of shares
required in connection with the reverse stock split to enable the allocation of
a rounded number of shares to every shareholder. As a result, each existing
shareholder will receive at least one share and in any event, a rounded number
of shares.

The nominal value of the shares that may be issued under the conditional and the
authorized capital is to be changed from CHF 0.01 to CHF 1.00 as well to enable
the future issuance of a round number of shares.

Messrs Dominik Ellenrieder and Vincent Ossipow do not stand for re-election as
member of the Board. The Board of Directors proposes to elect Leanna Caron as
new member of the Board. Mrs Caron is Executive Vice President and Chief
Commercial Officer for AgNovos Healthcare. A healthcare executive for the past
20 years, she developed an acumen in business development, strategic planning
and partnerships, global marketing, and overall business management. Mrs Caron
received her Pharmacy degree from the University of Toronto and her MBA from
Concordia and Cornell Universities.

The formal invitation to the meeting will be sent out within the next few days
and can also be downloaded from the following

For further information, please contact:
Kuros Biosciences Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46

About Kuros Biosciences Ltd

Kuros Biosciences Ltd is focused on the development of innovative products for
tissue repair and regeneration and is located in Schlieren (Zurich),
Switzerland. The Company is listed according to the Main Standard on the SIX
Swiss Exchange Ltd under the symbol KURN. Information regarding Kuros is
available atwww.kuros.ch.

Forward Looking Statements
This media release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. You are urged to consider statements
that include the words "will" or "expect" or the negative of those words or
other similar words to be uncertain and forward-looking. Factors that may cause
actual results to differ materially from any future results expressed or implied
by any forward-looking statements include scientific, business, economic and
financial factors, Against the background of these uncertainties, readers should
not rely on forward-looking statements. The Company assumes no responsibility
for updating forward-looking statements or adapting them to future events or


End of ad hoc announcement
Additional features:

Document title: Kuros_AGM Invitation

26.05.2016 News transmitted by Tensid EQS AG. www.eqs.com

The issuer is responsible for the contents of the release.

Language: English

Company:  Kuros Biosciences AG

          Wagistrasse 25

          8952  Schlieren


Phone:    +41 44 733 4747

Fax:      +41 44 733 4740


Internet: www.kuros.ch

ISIN:     CH0011025217

Valor:    -

Listed:   Foreign Exchange(s) SIX

End of News EQS Group News Service
466703  26.05.2016 

Weitere Meldungen: Kuros Biosciences AG

Das könnte Sie auch interessieren: